Aspira Women's Health Stock Forecast, Price & News

+0.36 (+10.88 %)
(As of 09/17/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume1.73 million shs
Average Volume601,387 shs
Market Capitalization$411.29 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive AWH News and Ratings via Email

Sign-up to receive the latest news and ratings for Aspira Women's Health and its competitors with MarketBeat's FREE daily newsletter.

Aspira Women

About Aspira Women's Health

Aspira Women's Health, Inc. engages in the provision of bio-analytic and diagnostic services. Its product, OVA1, is a serum test for identifying women of having malignant ovarian tumor. Its bio-analytical solutions helps physicians diagnose, treat, and improve gynecologic health outcomes for women. The company was founded on December 9, 1993 and is headquartered in Austin, TX.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.64 out of 5 stars

Medical Sector

940th out of 1,349 stocks

Diagnostic Substances Industry

12th out of 25 stocks

Analyst Opinion: 3.4Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Aspira Women's Health (NASDAQ:AWH) Frequently Asked Questions

Is Aspira Women's Health a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aspira Women's Health in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Aspira Women's Health stock.
View analyst ratings for Aspira Women's Health
or view top-rated stocks.

What stocks does MarketBeat like better than Aspira Women's Health?

Wall Street analysts have given Aspira Women's Health a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Aspira Women's Health wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Aspira Women's Health's next earnings date?

Aspira Women's Health is scheduled to release its next quarterly earnings announcement on Thursday, November 11th 2021.
View our earnings forecast for Aspira Women's Health

How were Aspira Women's Health's earnings last quarter?

Aspira Women's Health Inc. (NASDAQ:AWH) released its quarterly earnings data on Wednesday, August, 11th. The company reported ($0.06) EPS for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.06). The business earned $1.80 million during the quarter, compared to analysts' expectations of $1.70 million. Aspira Women's Health had a negative net margin of 390.67% and a negative trailing twelve-month return on equity of 75.71%.
View Aspira Women's Health's earnings history

What price target have analysts set for AWH?

6 analysts have issued twelve-month price targets for Aspira Women's Health's stock. Their forecasts range from $10.00 to $12.00. On average, they expect Aspira Women's Health's stock price to reach $11.33 in the next twelve months. This suggests a possible upside of 208.8% from the stock's current price.
View analysts' price targets for Aspira Women's Health
or view top-rated stocks among Wall Street analysts.

Who are Aspira Women's Health's key executives?

Aspira Women's Health's management team includes the following people:
  • Valerie Barber Palmieri, President, Chief Executive Officer & Director
  • Kaile Zagger, Chief Operating Officer
  • Robert Beechey, Chief Financial Officer
  • Lesley Northrop, Chief Scientific Officer
  • Justin DeGrazia, Senior Director-Research & Development

What is Scott A. Carmilani's approval rating as Aspira Women's Health's CEO?

22 employees have rated Aspira Women's Health CEO Scott A. Carmilani on Scott A. Carmilani has an approval rating of 92% among Aspira Women's Health's employees. This puts Scott A. Carmilani in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Aspira Women's Health's key competitors?

What other stocks do shareholders of Aspira Women's Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aspira Women's Health investors own include AcelRx Pharmaceuticals (ACRX), Aptinyx (APTX), Axcella Health (AXLA), Aytu Biopharma (AYTU), Calithera Biosciences (CALA), Cidara Therapeutics (CDTX), Catalyst Pharmaceuticals (CPRX), DURECT (DRRX), Geron (GERN) and LiveXLive Media (LIVX).

What is Aspira Women's Health's stock symbol?

Aspira Women's Health trades on the NASDAQ under the ticker symbol "AWH."

Who are Aspira Women's Health's major shareholders?

Aspira Women's Health's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (4.15%), Vanguard Group Inc. (2.67%), State Street Corp (2.00%), Geode Capital Management LLC (1.04%), Northern Trust Corp (0.65%) and B. Riley Wealth Management Inc. (0.42%). Company insiders that own Aspira Women's Health stock include David Schreiber and Jack W Schuler.
View institutional ownership trends for Aspira Women's Health

Which major investors are selling Aspira Women's Health stock?

AWH stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Wells Fargo & Company MN, Bridgeway Capital Management LLC, Northern Trust Corp, Vanguard Group Inc., Bank of America Corp DE, Investment Management of Virginia LLC, and Geode Capital Management LLC.
View insider buying and selling activity for Aspira Women's Health
or view top insider-selling stocks.

Which major investors are buying Aspira Women's Health stock?

AWH stock was purchased by a variety of institutional investors in the last quarter, including Greenwich Wealth Management LLC, Millennium Management LLC, Swiss National Bank, Renaissance Technologies LLC, State Street Corp, B. Riley Wealth Management Inc., Ergoteles LLC, and UBS Asset Management Americas Inc..
View insider buying and selling activity for Aspira Women's Health
or or view top insider-buying stocks.

How do I buy shares of Aspira Women's Health?

Shares of AWH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aspira Women's Health's stock price today?

One share of AWH stock can currently be purchased for approximately $3.67.

How much money does Aspira Women's Health make?

Aspira Women's Health has a market capitalization of $411.29 million and generates $4.65 million in revenue each year. The company earns $-17,910,000.00 in net income (profit) each year or ($0.18) on an earnings per share basis.

How many employees does Aspira Women's Health have?

Aspira Women's Health employs 69 workers across the globe.

What is Aspira Women's Health's official website?

The official website for Aspira Women's Health is

Where are Aspira Women's Health's headquarters?

Aspira Women's Health is headquartered at 12117 BEE CAVES ROAD BUILDING THREE SUITE 100, AUSTIN TX, 78738.

How can I contact Aspira Women's Health?

Aspira Women's Health's mailing address is 12117 BEE CAVES ROAD BUILDING THREE SUITE 100, AUSTIN TX, 78738. The company can be reached via phone at (512) 519-0400 or via email at [email protected].

This page was last updated on 9/20/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.